Jones, Peter H <br/><br/>
Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials.  [electronic resource] 

 -  The American journal of cardiology  Dec 2016 
 - 1805-1811 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1879-1913 
<br/><br/><label>Standard No.: </label>10.1016/j.amjcard.2016.08.072  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Coronary Syndrome--epidemiology<br/>Aged<br/>Angina, Unstable--epidemiology<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Anticholesteremic Agents--adverse effects<br/>Back Pain--chemically induced<br/>Clinical Trials, Phase II as Topic<br/>Clinical Trials, Phase III as Topic<br/>Comorbidity<br/>Coronary Disease--epidemiology<br/>Diabetes Mellitus, Type 2--epidemiology<br/>Ezetimibe--adverse effects<br/>Humans<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--therapeutic use<br/>Hypercholesterolemia--drug therapy<br/>Influenza, Human--chemically induced<br/>Middle Aged<br/>Myocardial Infarction--epidemiology<br/>Nasopharyngitis--chemically induced<br/>Pruritus--chemically induced<br/>Randomized Controlled Trials as Topic<br/>Respiratory Tract Infections--chemically induced<br/>Stroke--epidemiology<br/>Urinary Tract Infections--chemically induced